WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS).
Diclofenac sodium delayed-release tablets are contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS, WARNINGS). Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.
These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events (see WARNINGS).
Use: Labeled indications
- For relief of the signs and symptoms of osteoarthritis
- For relief of the signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis
Full indications and usage US FDA label
INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).
Diclofenac sodium delayed-release tablets are indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis
Contraindications
- Hypersensitivity to the drug
- Asthma, urticaria or allergic-type reaction after aspirin or other NSAIDs
- Setting of coronary artery bypass graft (CABG) surgery
Contraindications (US label) US FDA label
CONTRAINDICATIONS Diclofenac sodium delayed-release tablets are contraindicated in the following patients: Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS; Anaphylactic Reactions, Serious Skin Reactions). History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS; Anaphylactic Reactions, PRECAUTIONS; Exacerbation of Asthma Related to Aspirin Sensitivity). In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS; Cardiovascular Thrombotic Events).
Dosing: Adult
- Osteoarthritis: 100 to 150 mg/day in divided doses (50 mg two or three times daily, or 75 mg twice daily)
- Rheumatoid arthritis: 150 to 200 mg/day in divided doses
- Ankylosing spondylitis: 100 to 125 mg/day (25 mg four times daily, plus 25 mg at bedtime if needed)
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation).
After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient’s needs. For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).
For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day. or four times a day, or 75 mg twice a day.). For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25-mg dose at bedtime if necessary.
Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets, diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.
Dosing: Altered kidney function
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) cleared by liver metabolism; its pharmacokinetics do not change in kidney impairment. The kidney concern is injury, not accumulation: the US label advises avoiding it in advanced kidney disease unless benefits outweigh the risk and monitoring kidney function, potassium and blood pressure in anyone at risk.
Kidney function measure: Label PK study used inulin clearance (60–90, 30–60, <30 mL/min); warnings use 'advanced renal disease' without a number. Mapping 'advanced' to CrCl <30 is our judgment.
Show full dosing details
- CrCl ≥60 mL/min
- Usual dose by indication: osteoarthritis 100 to 150 mg/day, rheumatoid arthritis 150 to 200 mg/day, in divided doses (label). Lowest effective dose, shortest duration.
- CrCl 30–59 mL/min
- No dose change (pharmacokinetics unchanged; label). Kidney impairment raises the risk of NSAID kidney injury: monitor creatinine, potassium and blood pressure; avoid volume depletion and the ACE inhibitor or ARB plus diuretic combination.
- CrCl 15–29 mL/min
- No information from controlled studies in advanced kidney disease; avoid unless benefits outweigh the risk of worsening kidney function, and if used monitor kidney function (label, Renal Toxicity). Pharmacokinetics are unchanged in kidney impairment (inulin clearance down to <30 mL/min), so the risk is kidney injury, not accumulation.
- CrCl <15 mL/min (not on dialysis)
- No information from controlled studies in advanced kidney disease; avoid unless benefits outweigh the risk of worsening kidney function, and if used monitor kidney function (label, Renal Toxicity). Pharmacokinetics are unchanged in kidney impairment (inulin clearance down to <30 mL/min), so the risk is kidney injury, not accumulation.
- Hemodialysis (intermittent)
- Avoid unless benefits outweigh the risk (advanced kidney disease; label). Not removed by dialysis (over 99% protein-bound). NSAIDs may hasten loss of residual kidney function.
- Peritoneal dialysis
- Avoid unless benefits outweigh the risk (label). NSAIDs may hasten loss of residual kidney function.
- CRRT
- Avoid: NSAIDs can worsen acute kidney injury.
- Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (over 99%; label).
- Monitoring Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Liver enzymes within 4 to 8 weeks of starting long-term use (diclofenac hepatotoxicity warning).
Children (kidney dosing)
- eGFR ≥60
- Not approved for children; kidney dosing not applicable.
- eGFR 30–59
- Not approved for children; kidney dosing not applicable.
- eGFR 15–29
- Not approved for children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not approved for children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not approved for children; kidney dosing not applicable.
- Peritoneal dialysis
- Not approved for children; kidney dosing not applicable.
- CRRT
- Not approved for children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Renal Impairment: Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and less than 30 mL/min; N = 6 in each group), area under the curve (AUC) values and elimination rate were comparable to those in healthy subjects.
Dosing: Pediatric
- Approved ages
- Not established in pediatric patients (label).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Enteric-coated tablet: 25 mg, 50 mg
- Solution for injection: 25 mg/mL
- ) solution for injection: 25 mg/mL (75 mg/3 mL
- Rectal suppository: 12.5 mg, 25 mg, 50 mg, 100 mg
- Sustained-release tablet: 100 mg
- Film-coated tablet: 50 mg, 100 mg
- Gel: 1 g/100 g, 10 mg/g
- Topical gel: 10 mg/g, 18.6 mg/g
- Diclofenac diethylamine) topical gel: 10 mg/g (1 % w/w) (equivalent to 11.6 mg, 10 mg/g (equivalent to 11.6 mg/g
- Enteric film-coated tablet: 50 mg
and 15 more forms; see the products table.
Registered products in the Philippines
117 products registered with the Food and Drug Administration (FDA) Philippines list Diclofenac as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Diclofenac Diethylamine (8 products, possible match).
All registered products117
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcuflamDiclofenac Sodium | 10 mg/g (1 % w/w) Topical SprayOpaque white HDPE Bottle with HDPE cap x 60 mL (Box of 1's) | OTC | Unison Laboratories Co., Ltd.Thailand | JustRight Healthcare Inc. | DR-XY46381 | Aug 20, 2028 | |
Alisakit PlasterDiclofenac (as Sodium) | 15 mg PlasterPolyethylene-aluminum Pouch x 7's (Box of 50 pouches) | Rx | Sinil Pharmaceutical Co., Ltd.Korea | Ambica International Corporation | DR-XY49206 | Sep 13, 2029 | |
ArnilDiclofenac Sodium (as diethylamine) | 1 g/100 g GelAluminum Tube x 20 g (Box of 1's) | Rx | Brookes Pharma Private LimitedPakistan | Sahar International Trading Inc. | DR-XY43001 | Nov 22, 2028 | |
Atornac KDiclofenac Potassium | 50 mg Enteric-Coated TabletAlu-PVC Blister Pack x 10's (Box of 30's) | Rx | Pell Tech Health Care Pvt. Ltd.India | Ambica International Corporation | DRP-9933 | Aug 14, 2030 | |
BlifecDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution For Injection (I.M.)USP Type I Amber Glass Ampoule in a PVC Tray x 3 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-13628 | Mar 23, 2028 | |
BorenDiclofenac (as sodium) | 25mg/mL Solution for Injection (I.M./I.V.)USP Type III Amber Glass Ampoule x 3mL (10 ampoules/plastic tray) Box of 10's & 100's | Rx | Reyoung Pharmaceutical Co. Ltd.China | Health Saver Pharma Inc. | DRP-2027 | Jul 24, 2027 | |
BorenDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-18011 | Dec 5, 2030 | |
BorenDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-3882 | May 25, 2029 | |
CatafenDiclofenac Sodium | 50 mg SuppositoryPVC/PE Film Strip x 5's (Box of 10's) | Rx | Bliss GVS Pharma Ltd.India | Endure Medical Inc. | DR-XY44207 | Feb 13, 2030 | |
CataflamDiclofenac potassium | 25 mg Sugar-Coated TabletBlister Pack x 10’s (Box of 100’s); Blister Pack x 10’s (Box of 10’s) (as Physician’s Sample) | Rx | Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic A.S.Turkey | Novartis Healthcare Philippines, Inc. | DRP-4018 | Jan 18, 2031 | |
CataflamDiclofenac Potassium | 50 mg Sugar-Coated TabletPVC/PE/PVDC Blister pack x 10's Box of 100's; PVC/PE/PVDC Blister pack x 10's Box of 10's [as physician's sample] | Rx | Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret, A.S.Turkey | Novartis Healthcare Philippines, Inc. | DRP-7687 | Feb 1, 2029 | |
CataflinDiclofenac Potassium | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | — | Phil. Pharmawealth, Inc. | DR-XY34228 | Jan 31, 2028 | |
ClodifloxDiclofenac sodium | 50 mg Rectal SuppositoryPVC/PE Blister Film x 5’s (Box of 100’s) | Rx | Farmaprim Ltd.Republic of Moldova | Ambica International Corporation | DRP-8967 | Aug 17, 2037 | |
ClofefarDiclofenac Sodium | 100 mg Sustained-Release TabletAluminum Strip x 10’s (Box of 20's) | Rx | Agio Pharmaceuticals Ltd.India | JJYSRINN Trading Inc.Importer: Ambica International Corporation | DRP-978-01 | May 19, 2030 | |
ClofefarDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | JJYSRINN TRADING INC.Importer: Ambica International Corporation | DRP-2893-02 | Mar 19, 2030 | |
ClofenadDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | SAPPHIRE LIFESCIENCES PVT. LTDIndia | 777 Red Pharma IncImporter: NELPA LIFESCIENCES, INC. | DRP-5609-01 | Oct 15, 2029 | |
CLOFENADDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Genom Biotech Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-5609-02 | Mar 24, 2031 | |
Clofenex-50Diclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Vispomed EnterprisesImporter: Ambica International Corporation | DRP-2893 | Mar 19, 2030 | |
ClofenovaDiclofenac Potassium | 50 mg Film-Coated TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's) | Rx | SAGA LIFESCIENCES LIMITEDIndia | GA2 Pharmaceutical Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8456-01 | Nov 28, 2028 | |
ClofepenDiclofenac (As Sodium) | 50 mg Enteric-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Multigro Healthcare Inc.Importer: Grovic Pharma Inc. | DRP-5152-04 | Dec 23, 2029 | |
ClofezestDiclofenac Sodium | 25 mg/mL (75 mg/ 3 mL) Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule x 3 mL (Box of 5's) | Rx | East African (India) OverseasIndia | Ambica International Corporation | DRP-13008 | Nov 16, 2027 | |
ClogelDiclofenac (as Diethylamine) | 10 mg/g (1% w/w) Topical GelAluminum tube x 20 g (Box of 1's) | OTC | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY35746 | Apr 27, 2029 | |
ClopichemDiclofenac sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | ChemEx Logistics and Trading Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-2652-04 | Jun 4, 2027 | |
CoxynDiclofenac sodium (equivalent to Diclofenac diethylamine) | 10 mg/g (1%w/w) Topical GelAluminum collapsible tube x 30 g (Box of 1's) | Rx | Lincoln Pharmaceuticals Ltd.India | Despina Pharma Inc. | DRP-12834 | Oct 12, 2027 | |
CurafenDiclofenac Sodium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | The ACME Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DRP-6386 | Jan 7, 2028 | |
DafenacDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (IM)USP Type I Clear Glass Ampoule x 3 mL (Box of 10's) | Rx | Gland Pharma LimitedIndia | Endure Medical, Inc. | DR-XY35969 | Jun 8, 2029 | |
DefnacDiclofenac Sodium | 25 mg/ mL Solution for InjectionUSP Type I Amber Glass Ampoule x 3 mL (Box of 5’s) | Rx | The Searle Company LimitedPakistan | Ambica International Corporation | DR-XY40922 | Jun 15, 2030 | |
DiclaustinDiclofenac Sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Paramed Pharmaceuticals, Inc.Trader: Eadriex Pharmaceuticals Phils., Inc | DRP-2257-01 | Feb 19, 2027 | |
DiclocareDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (IM/IV)3 mL USP Type Amber Glass Ampoule (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc. | DRP-9040-01 | Oct 24, 2031 | |
DiclofamDiclofenac sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-2652 | Jun 4, 2027 | |
Diclofen-50Diclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-17382-01 | Dec 5, 2030 | |
Diclofen-50Diclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Centurion Remedies Pvt. Ltd.India | TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-3882-01 | May 25, 2029 | |
DiclogenDiclofenac Sodium | 100 mg Sustained-Release TabletAluminum Strip x 10’s Box of 20’s and 100’s | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-978 | May 19, 2030 | |
DiclogenDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (I.M.)Type I Clear Colorless Glass Ampoule x 3 mL (Box of 5's) | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-5697 | Nov 7, 2030 | |
Diclollen-GE100Diclofenac sodium | 100 mg Sustained-Release TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Ollen Pharma Trading Inc. | DRP-17852 | Mar 25, 2031 | |
DiclominDiclofenac (as Sodium) | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | Neos-King Pharma Inc.Importer: Grovic Pharma Inc. | DRP-5152-02 | Dec 23, 2029 | |
DiclonacDiclofenac Sodium | 50 mg Enteric Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-2193-01 | Aug 28, 2027 | |
DiclophilDiclofenac (as sodium) | 25mg/mL (75mg/3mL) Solution for Injection (I.M./I.V.)Amber Glass Ampoule x 3 mL (Box of 10's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-12104 | Jun 13, 2027 | |
DiclophilDiclofenac sodium | 25mg/mL Solution for Injection (IM/IV)Type I Clear Glass Ampoule with Blue dot x 3mL in PVC Tray (Box of 10's) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc. | DRP-17324 | Nov 14, 2030 | |
Dicloran GelDiclofenac Sodium | 10 mg/g (1% w/w) Topical GelLacquer Coated Aluminum Collapsible Tube x 20 g (Box of 1’s) | Rx | Unique Pharmaceuticals Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Ltd.)India | JBCPL Philippines Inc. | DRP-4169 | Jan 3, 2028 | |
DiclosafeDiclofenac Sodium | 100 mg Rectal SuppositoryWhite PVC/PE strip of 5's (Box of 10's) | Rx | Kusum Healthcare Pvt. Ltd. (Block II)India | Kusum Healthcare Private Limited Branch Office | DR-XY48209 | Jul 21, 2027 | |
DiclosafeDiclofenac sodium | 50 mg Rectal SuppositoryPVC/PE Strip x 5's (Box of 10's) | Rx | Kusum Healthcare Pvt. Ltd. (Block III)India | Kusum Healthcare Private Limited Branch Office | DR-XY46946 | Aug 17, 2030 | |
DiclosaphDiclofenac Sodium | 25mg/mL Solution For Injection (IM/IV)USP Type I flint glass ampoule x 3 mL (Box of 5 ampoules in white plastic tray) | Rx | Kilitch Drugs (I) Ltd.India | Nelpa Lifesciences, Inc. | DRP-11194 | Feb 11, 2027 | |
DicloseaDiclofenac (as sodium) | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | S Kant Healthcare Ltd.India | SEA-King Pharma Inc.Importer: Grovic Pharma Inc. | DRP-5152-03 | Dec 23, 2029 | |
DiclotrueDiclofenac Sodium | 25 mg/ mL Solution for Injection (IM/IV)USP Type I glass ampoule x 3 mL (Box of 10 ampoules in a plastic tray) | Rx | Cooper Pharma LimitedIndia | Ambica International Corporation | DRP-12487 | Aug 18, 2027 | |
DicloxDiclofenac Sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | 999 Seth Pharmaceutical Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-2193 | Aug 28, 2027 | |
DicloxiriDiclofenac Sodium | 25 mg/mL (75 mg/ 3 mL) Solution for Injection (I.M./I.V.)USP Type I amber coloured glass ampoule x 3 mL | Rx | Pharmax India Private LimitedIndia | Ambica International CorporationTrader: Rainbow Life Sciences Pvt. Ltd. | DRP-13007 | Nov 16, 2027 | |
DiclozedDiclofenac sodium | 25 mg/mL Solution for Injection (IM/IV)Clear Glass Ampoule x 5 mL (Box of 10's) | Rx | Sakar Healthcare Pvt. Ltd.India | Macropharma Corporation | DRP-10854 | Dec 9, 2031 | |
DicofenDiclofenac Sodium | 25 mg/mL Solution for Injection (IM/IV)3 mL USP Type I Amber Glass Ampoule with Red and Blue Ring (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Endure Medical Inc. | DR-XY44146 | Feb 11, 2030 | |
DictasDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Umedica Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-8220 | Mar 18, 2029 | |
DifenaminDiclofenac Sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-545 | May 13, 2027 | |
Difenax (reformulated)Diclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY33250 | Aug 1, 2028 | |
DiflacDiclofenac Potassium | 50 mg Film-Coated TabletAlu-Clear PVC blister pack by 10’s Box of 100’s | Rx | SAGA LIFESCIENCES LIMITEDIndia | MEDINOVA PHARMACEUTICAL INC. | DRP-8456 | Nov 28, 2028 | |
DiflonaxDiclofenac (as sodium) | 25 mg/mL Solution for Injection (IM/IV)Type I glass ampoule packed in tray x 3 mL (Box of 10's) | Rx | Psychotropics India Limited (General Block)India | Despina Pharma Inc. | DRP-15594 | Aug 14, 2029 | |
DiflosidDiclofenac (as sodium) | 25 mg/mL Solution for Injection (IM/IV)USP Type I Glass Ampoule x 3 mL in 2 Plastic Trays x 5's Box of 10's | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading Inc. | DRP-6689 | Jul 30, 2029 | |
DiklonacDiclofenac | 10 mg/g (1% w/w) GelAluminum Collapsile Tube x 30 g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Aglobal Care, Inc. | DRP-12755 | Oct 6, 2027 | |
DitionDiclofenac Sodium | 1 g (equivalent to Diclofenac Diethylamine) (1% w/w) per 100g Topical Gel Topical GelAluminum Tube x 20 g (Box of 1's) | OTC | S Kant Healthcare LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-10798 | Nov 25, 2026 | |
DolfenDiclofenac Sodium | 25 mg/mL (75 mg/3mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 3 mL (Box of 10's) | Rx | Swiss Parenterals, Ltd.India | Endure Medical, Inc. | DR-XY41180 | Aug 28, 2027 | |
DosanacDiclofenac Sodium | 25 mg/mL Solution for Injection (IM)Clear/Colorless Glass Ampoule in a blister tray x 10's (Box of 50's) | Rx | T.P. Drug Laboratories (1969) Co., Ltd.Thailand | Lordla Pharma Sales | DRP-707 | Mar 2, 2029 | |
DycloDiclofenac Sodium | 25 mg/mL Solution For Injection (IM/IV)USP Type I Amber Glass Ampoule x 3 mL (Box of 4 Alu/PVC blister packs x 5 ampoules) | Rx | Indus Pharma (Pvt.) Ltd.Pakistan | One Dexcel Pharma Inc. | DRP-11899 | May 18, 2027 | |
DyflarenDiclofenac (as sodium) | 25 mg/mL (75 mg/3 mL) Solution for Injection3 mL USP Type I Clear Colorless Glass Ampoule (Box of 10’s in a plastic tray) | Rx | Venus InternationalIndia | AGB Pharmaceutical Trading and Consultancy Corp.Importer: Ambica International Corporation | DRP-4174-01 | Nov 27, 2028 | |
Dynapar-ECDiclofenac (as sodium) | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines, Inc. | DR-XY42654 | Sep 17, 2028 | |
Dynapar-SR 100Diclofenac (as sodium) | 100mg Sustained Release TabletAlu/PVC Blister Pack x 10's ( Box of 100's) | Rx | Troikaa Pharmaceuticals LimitedIndia | Troikaa Pharmaceuticals Philippines, Inc. | DR-XY42541 | Jan 3, 2029 | |
ErdonDiclofenac Sodium( as diethylamine) | 10 mg/g (1% w/w) Gel10 g Aluminum Collapsible tube Box of 1's | Rx | Aristopharma LtdBangladesh | Sahar International Trading Inc | DR-XY45469 | Jun 30, 2031 | |
F-DicloDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (IM/IV)3 mL USP Type Amber Glass Ampoule (Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Aglobal Care Inc. | DRP-9040 | Sep 24, 2030 | |
FencidDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Reta DrugTrader: Westfield Pharmaceuticals, Inc. | DRP-2652-02 | Jun 4, 2027 | |
FlexgelDiclofenac (as diethylamine) | 10mg/g (1%w/w)Topical Gel25 g Aluminum Collapsible Tube in a Box | Rx | The United Drug (1996) Co., Ltd.Thailand | Endure Medical, Inc.Importer: Singapore Genebio, Inc. | DR-XY41463 | Dec 12, 2027 | |
Globanac 50Diclofenac Sodium | 50 mg Enteric-Coated TabletAlu/ Clear PVC Blister pack x 10’s (Box of 100's) | Rx | AKRITI PHARMACEUTICALS PVT. LTD.India | AGLOBAL CARE, INC.Trader: PPJ PHARMA PVT. LTD. | DRP-8107 | Jun 6, 2027 | |
GofenacDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (I.M.)Type I Clear Colorless Glass Ampoule x 3 mL (Box of 5's) | Rx | Agio Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution IncImporter: Ambica International Corporation | DRP-5697-01 | Nov 7, 2030 | |
Healthcare Joint PainDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY39262 (For Export Only) | Apr 5, 2030 | |
LofenaxDiclofenac Sodium | 25 mg/mL Solution for InjectionUSP Type I Amber Glass Ampoule 3 mL (Box of 10's) | Rx | Geofman PharmaceuticalsPakistan | Clinbaxy International, Inc. | DR-XY30144 | Oct 15, 2027 | |
LufenacDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/ Clear PVC Blister pack X 10’s (Box of 100’S) | Rx | Akriti Pharmaceuticals Pvt. Ltd.India | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC.Trader: PPJ PHARMA PVT. LTD. | DRP-8107-01 | Jun 6, 2027 | |
MedclofDiclofenac sodium | 25 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 3 mL (In Blister Pack x 5’s) (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Nutramedica Inc.Importer: Medbridge, Inc. | DR-XY34034 | Dec 6, 2030 | |
MesofidDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | MeedPharma Medical Supplies & Equipment DistributorTrader: Westfield Pharmaceutical, Inc. | DRP-2652-01 | Jun 4, 2027 | |
MinefenacDiclofenac Sodium | 25mg/mL (75mg/3mL) Solution For Injection (IM/IV)USP Type I Clear/Colourless Glass Ampoule x 3 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Diafarm Inc. | DRP-17313 | Nov 13, 2030 | |
MioclofDiclofenac (as sodium) | 25 mg/mL (75 mg/3 mL) Solution for Injection3 mL USP Type I Clear Colorless Glass Ampoule (Box of 10’s in a plastic tray) | Rx | Venus InternationalIndia | Ambica International Corporation | DRP-4174 | Nov 27, 2028 | |
MuscortexDiclofenac sodium | 50 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Foramen Products Corporation | DR-XY31415 | Apr 4, 2030 | |
Neo-PyrazonDiclofenac Sodium | 50 mg Enteric Film-Coated TabletAluminum Flex Foil x 4's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-2612 | Jun 25, 2028 | |
NoneDiclofenac Sodium | 50 mg Enteric Film-Coated TabletAluminum Flex Foil x 4's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | RiteMED Phils., Inc.Trader: UNILAB, Inc. | DRP-2612-02 | Jun 25, 2028 | |
NoneDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-2652-03 | Jun 4, 2027 | |
NoneDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | ATC Healthcare International Corp.Importer: Ambica International Corporation | DRP-2893-03 | Mar 19, 2030 | |
NoneDiclofenac (As Sodium) | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's Box of 100's | Rx | S KANT HEALTHCARE LTD.India | ACTIMED, INC.Importer: GROVIC PHARMA INC. | DRP-5152 | Dec 23, 2029 | |
NovanacDiclofenac Sodium | 25mg/mL (75mg/3mL) Solution For Injection (IM/IV)3 mL USP Type I amber glass ampoule | Rx | Bharat Parenterals, LimitedIndia | Medinova Pharmaceutical Inc. | DRP-19087 | Oct 27, 2031 | |
PhenylacDiclofenac Sodium | 25 mg/mL Solution For Injection (I.M./I.V.)3 mL USP Type I glass ampoule in PVC tray (Box of 5's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-13305 | Jan 23, 2028 | |
Philflam DRDiclofenac Sodium | 50 mg Delayed-Release TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-7975 | Mar 16, 2031 | |
QuickierDiclofenac | 10 mg/g (1% w/w) (equivalent to 11.6 mg Diclofenac Diethylamine) Topical GelLaminated Tube x 10 g and 20 g (Box of 1's) | OTC | Fredun Pharmaceuticals Ltd.India | AMB HK Enterprises Inc. | DRP-11869 | May 12, 2027 | |
RheudiDiclofenac (as Sodium) | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY33750 | Aug 22, 2027 | |
RheuflamDiclofenac Sodium | 25 mg/mL (75 mg/3 mL) Solution for Injection (IM)Amber Glass Ampoule x 3 mL (Box of 10's) | Rx | STANDARD CHEM. & PHARM. CO., LTD.Taiwan | PHIL. PHARMAWEALTH, INC. | DR-XY23782 | Jan 23, 2028 | |
RinefenDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10’s Box of 100’s | Rx | Umedica Laboratories Pvt. Ltd.India | Jjysrinn Trading Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-8220-01 | Mar 18, 2029 | |
SaphlocidDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-5609 | Mar 24, 2031 | |
SitiflamDiclofenac Sodium | 50mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's and 100's) | Rx | Hubei Huazhong Pharmaceutical Co., Ltd.China | SAHAR INSahar International Trading, Inc.TERNATIONAL TRADING INC.Importer: Sahar International Trading, Inc. | DR-XY41561 | Jan 3, 2028 | |
Subsyde-CRDiclofenac Sodium | 100 mg Controlled-Release CapsuleBlister Strip x 10's Box of 100's | Rx | Raptakos, Brett & Co. Ltd.India | Raptakos, Brett & Co. Ltd. | DRP-1727 | Aug 12, 2027 | |
TrifocidDiclofenac Sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc. | DRP-2257 | Feb 19, 2027 | |
UnbrandedDiclofenac Sodium | 25 mg Enteric Coated TabletAlu/Clear PVC Blister Pack x 20's Box of 100's | Rx | Drugmaker’s Laboratories Inc.Philippines | — | DRP-8062 | Jun 23, 2029 | |
UnbrandedDiclofenac Sodium | 50 mg Enteric-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Diafarm Inc. | DRP-2893-01 | Mar 19, 2030 | |
Vantelin GelDiclofenac Sodium | 10 mg (1% w/w) per g Topical GelAluminum Tube x 20 g & 45 g (Box of 1's) | OTC | Y.S.P. Industries (M) SDN. BHDMalaysia | DKSH Market Expansion Services Philippines, Inc. | DR-XY49364 | Mar 25, 2030 | |
VindicloDiclofenac Sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Vincare PharmaTrader: Eadriex Pharmaceuticals Phils., Inc. | DRP-2257-02 | Feb 19, 2027 | |
VodefenDiclofenac Potassium | 50 mg Enteric-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Mercury Laboratories Ltd.India | Phil Pharmawealth, Inc. | DR-XY38791 | Nov 25, 2030 | |
VoltarenDiclofenac Sodium | 25 mg Enteric Coated TabletPVC/PE/PVDC (Triplex) Blister Pack backed with a heat-sealable lacquered aluminum foil x 10’s (Box of 100's); PVC/PE/PVDC (Triplex) Blister Pack backed with a heat-sealable lacquered aluminum foil x 10’s (Box of 10's, as Physician's Sample) | Rx | Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic. A.S.Turkey | Importer: Novartis Healthcare Philippines, Inc. | DR-XY28428 | Mar 19, 2028 | |
VoltarenDiclofenac Sodium | 25 mg/mL Solution for Injection (IM/IV)Colorless Glass Ampoule x 3 mL Box of 10's | Rx | Lek Pharmaceuticals D.D.Slovenia | Importer: Novartis Healthcare Philippines, Inc. | DR-X1740 | Aug 20, 2027 | |
Voltaren EmulgelDiclofenac (as diethylamine) | 1 g/100 g (1%) EmulgelAluminum Tube with HDPE Screw Cap x 5 g and 20 g (Box of 1's) | OTC | GlaxoSmithKline Consumer Health Care Pakistan LimitedPakistan | Importer: GlaxoSmithKline Consumer Healthcare Philippines, Inc. | DR-XY27796 | Aug 29, 2027 | |
Voltaren Emulgel 12 HoursDiclofenac | 18.6mg/g (1.86% w/w) Topical GelAluminum Laminated Tube x 30g (Box of l’s | OTC | GSK Consumer Healthcare S.A.Switzerland | Importer: Glaxosmithkline Consumer Healthcare Philippines, Inc. | DR-XY47470 | Nov 16, 2026Past listed date | |
Voltaren ForteDiclofenac sodium | 50 mg Enteric-Coated TabletAlu/PVC/PE/PVDC Blister Pack x 10’s (Box of 100's) | Rx | Novartis Saglik, Gida Ve Tarim Urunleri San. Ve Tic. A.S.Turkey | Novartis Healthcare Philippines, Inc. | DR-XY27769 | Aug 19, 2027 | |
Voltaren SRDiclofenac Sodium | 100 mg Sustained-Release Film-Coated TabletPVC/PE/PVDC Blister Pack x 10's (Box of 10's and 100's) | Rx | Novartis Farma S.P.A.Italy | Importer: Novartis Healthcare Philippines, Inc. | DR-XY27795 | Apr 30, 2029 | |
VorenDiclofenac Sodium | 10 mg/g (1% w/w) GelAluminum Tube x 20 g Box of 1's | Rx | Y.S.P Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines),Inc. | DR-XY16632 | Oct 13, 2029 | |
VorenDiclofenac Sodium | 12.5 mg Rectal SuppositoryGreen-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY47668 | Jan 18, 2027 | |
VorenDiclofenac sodium | 25 mg Rectal SuppositoryBlue-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY47669 | Jan 18, 2032 | |
VorenDiclofenac Sodium | 25 mg/mL Solution for Injection (I.M.)Clear and Colorless Glass Ampoule x 3 mL (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd.Taiwan | Yung Shin (Philippines), Inc. | DR-XY12275 | Sep 17, 2029 | |
VorenDiclofenac sodium | 50 mg Enteric-Coated TabletBlister Pack x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Philgen Pharmaceuticals Inc. | DR-XY25662 | Nov 10, 2029 | |
VorenDiclofenac sodium | 50 mg Rectal SuppositoryRed-Colored PVC-Based Peel-Off Strip x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY47667 | Jan 18, 2032 | |
Voren ForteDiclofenac Sodium | 50 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Yung Shin Pharm. Ind. Co. Ltd.-Taichung Youth FactoryTaiwan | Yung Shin (Philippines),Inc. | DR-XY17218-B | Oct 21, 2029 | |
VovenilDiclofenac (as Sodium) | 25mg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 3 mL (Box of 5 ampoules x 3 mL) | Rx | Akums Drugs & Pharmaceuticals Ltd. (Plant III Injectables)India | Ambica International CorporationTrader: Unosource Pharma Ltd. | DRP-13141 | Dec 7, 2027 | |
ZobidDiclofenac Sodium | 25 mg/mL Solution for Injection (IM)3 mL USP Type I Clear Glass Ampoule x 10's in plastic tray per box | Rx | SM Pharmaceutical (M) Sdn. Bhd.Malaysia | Importer: PNF Pharmaceutical, Inc. | DRP-8321 | Apr 14, 2028 | |
ZolterolDiclofenac Sodium | 100 mg Sustained Release TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 100's) | Rx | Upha Pharmaceutical Mfg (M) Sdn BhdMalaysia | CCM International (Philippines), Inc.Trader: CCM Pharmaceuticals Sdn. Bhd. | DR-XY40513 | Jan 10, 2027 | |
(no brand name)Diclofenac (as diethylamine) | 10 mg/g (1% w/w) Topical GelLaminated Tube x 30 g (Box of 1's) | Rx | Rhydburg Pharmaceuticals Ltd.India | Khriz Pharma Trading Inc. | DRP-12105 | Jun 13, 2027 | |
(no brand name)Diclofenac Sodium | 10 mg/g (equivalent to 11.6 mg/g (1.16% w/w) Diclofenac Diethylamine) Topical GelLaminated Tube with Cap x 30 g (Box of 1’s) | OTC | Rhydburg Pharmaceuticals Ltd.India | Genedrift Philippines OPC | DRP-17925 | Apr 30, 2031 | |
(no brand name)Diclofenac Potassium | 50 mg Granules for Oral SolutionAluminum Flex Foil Sachet x 1.2 g (Box of 100 W Sachets) | Rx | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-10871 | Dec 9, 2026 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS Cardiovascular Thrombotic Events Clinical trials of several COX-2 selective and nonselective NSAIDs of up to 3 years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI), and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs.
The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease. However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate.
Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible.
Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur. There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use.
The concurrent use of aspirin and an NSAID, such as diclofenac, increases the risk of serious gastrointestinal (GI) events (see WARNINGS; Gastrointestinal Bleeding, Ulceration, and Perforation). Status Post Coronary Artery Bypass Graft (CABG) Surgery Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.
NSAIDs are contraindicated in the setting of CABG (see CONTRAINDICATIONS). Post-MI Patients Observational studies conducted in the Danish National Registry have demonstrated that patients treated with NSAIDs in the post-MI period were at increased risk of reinfarction, CV-related death, and all-cause mortality beginning in the first week of treatment.
In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients. Although the absolute rate of death declined somewhat after the first year post-MI, the increased relative risk of death in NSAID users persisted over at least the next four years of follow-up.
Avoid the use of diclofenac sodium delayed-release tablets in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If diclofenac sodium delayed-release tablets is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Gastrointestinal Bleeding, Ulceration, and Perforation NSAIDs, including diclofenac, can cause serious gastrointestinal (GI) adverse events, including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.
These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy, is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 - 6 months, and in about 2% - 4% of patients treated for one year.
However, even short-term therapy is not without risk. Risk Factors for GI Bleeding, Ulceration, and Perforation Patients with a prior history of peptic ulcer disease and/or GI bleeding who use NSAIDs had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors. Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status.
Most postmarketing reports of fatal GI events occurred in elderly or debilitated patients. Additionally, patients with advanced liver disease and/or coagulopathy are at increased risk for GI bleeding. Strategies to Minimize the GI Risks in NSAID-treated patients Use the lowest effective dosage for the shortest possible duration.
Avoid administration of more than one NSAID at a time Avoid use in patients at higher risk unless benefits are expected to outweigh the increased risk of bleeding. For such patients, as well as those with active GI bleeding, consider alternate therapies other than NSAIDs. Remain alert for signs and symptoms of GI ulceration and bleeding during NSAID therapy.
If a serious GI adverse event is suspected, promptly initiate evaluation and treatment, and discontinue diclofenac sodium delayed-release tablets until a serious GI adverse event is ruled out. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding (see PRECAUTIONS; Drug Interactions).
Hepatotoxicity In clinical trials of diclofenac-containing products, meaningful elevations (i.e., more than 3 times the upper limit of normal [ULN]) of aspartate aminotransferase (AST) (also known as SGOT) were observed in about 2% of approximately 5700 patients at some time during diclofenac treatment (alanine aminotransferase [ALT] was not measured in all studies). In a large, open-label, controlled trial of 3700 patients treated with oral diclofenac sodium for 2 to 6 months, patients were monitored first at 8 weeks and 1200 patients were monitored again at 24 weeks.
Meaningful elevations of ALT and/or AST occurred in about 4% of patients and included marked elevations (greater than 8 times the ULN) in about 1% of the 3700 patients. In that open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3 to 8 times the ULN), and marked (greater than 8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs.
Elevations in transaminases were seen more frequently in patients with osteoarthritis than in those with rheumatoid arthritis. Almost all meaningful elevations in transaminases were detected before patients became symptomatic. Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.
In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of therapy, but can occur at any time during treatment with diclofenac. Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure.
Some of these reported cases resulted in fatalities or liver transplantation. In a European retrospective population-based, case-controlled study, 10 cases of diclofenac associated drug- induced liver injury with current use compared with non-use of diclofenac were associated with a statistically significant 4-fold adjusted odds ratio of liver injury.
In this particular study, based on an overall number of 10 cases of liver injury associated with diclofenac, the adjusted odds ratio increased further with female gender, doses of 150 mg or more, and duration of use for more than 90 days. Physicians should measure transaminases at baseline and periodically in patients receiving long-term therapy with diclofenac, because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms.
The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.
If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, abdominal pain, diarrhea, dark urine, etc.), diclofenac sodium delayed-release tablets should be discontinued immediately. Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and "flu-like" symptoms).
If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., eosinophilia, rash, etc.), discontinue diclofenac sodium delayed-release tablets immediately, and perform a clinical evaluation of the patient. To minimize the potential risk for an adverse liver related event in patients treated with diclofenac sodium delayed-release tablets, use the lowest effective dose for the shortest duration possible.
Exercise caution when prescribing diclofenac sodium delayed-release tablets with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, antibiotics, anti- epileptics). Hypertension NSAIDs, including diclofenac sodium delayed-release tablets, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events.
Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazides diuretics, or loop diuretics may have impaired response to these therapies when taking NSAIDs (see PRECAUTIONS; Drug Interactions). Monitor blood pressure (BP) during the initiation of NSAID treatment and throughout the course of therapy. Heart Failure and Edema The Coxib and traditional NSAID Trialists’ Collaboration meta-analysis of randomized controlled trials demonstrated an approximately 2-fold increase in hospitalization for heart failure in COX-2 selective-treated patients and nonselective NSAID-treated patients compared to placebo-treated patients.
In a Danish National Registry study of patients with heart failure, NSAID use increased the risk of MI, hospitalization for heart failure, and death. Additionally, fluid retention and edema have been observed in some patients treated with NSAIDs. Use of diclofenac may blunt the CV effects of several therapeutic agents used to treat these medical conditions (e.g., diuretics, ACE inhibitors, or angiotensin receptor blockers [ARBs]) (see PRECAUTIONS; Drug Interactions).
Avoid the use of diclofenac sodium delayed-release tablets in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If diclofenac sodium delayed-release tablets is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.
Renal Toxicity and Hyperkalemia Renal Toxicity Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.
Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. No information is available from controlled clinical studies regarding the use of diclofenac sodium delayed-release tablets in patients with advanced renal disease.
The renal effects of diclofenac sodium delayed-release tablets may hasten the progression of renal dysfunction in patients with preexisting renal disease. Correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac sodium delayed-release tablets. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of diclofenac sodium delayed-release tablets (see PRECAUTIONS; Drug Interactions).
Avoid the use of diclofenac sodium delayed-release tablets in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If diclofenac sodium delayed-release tablets is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.
Hyperkalemia Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state. Anaphylactic Reactions Diclofenac has been associated with anaphylactic reactions in patients with and without known hypersensitivity to diclofenac and in patients with aspirin-sensitive asthma (see CONTRAINDICATIONS, WARNINGS; Exacerbation of Asthma Related to Aspirin Sensitivity).
Exacerbation of Asthma Related to Aspirin Sensitivity A subpopulation of patients with asthma may have aspirin-sensitive asthma, which may include chronic rhinosinusitis complicated by nasal polyps; severe, potentially fatal bronchospasm; and/or intolerance to aspirin and other NSAIDs. Because cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, diclofenac sodium delayed-release tablets is contraindicated in patients with this form of aspirin sensitivity (see CONTRAINDICATIONS).
When diclofenac sodium delayed-release tablets is used in patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma. Serious Skin Reactions NSAIDs, including diclofenac, can cause serious skin adverse reactions, such as exfoliative dermatitis, Stevens- Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.
These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions and to discontinue the use of diclofenac sodium delayed-release tablets at the first appearance of skin rash or any other sign of hypersensitivity. Diclofenac sodium delayed-release tablets is contraindicated in patients with previous serious skin reactions to NSAIDs (see CONTRAINDICATIONS).
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs, such as diclofenac sodium delayed-release tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling.
Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved.
It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue diclofenac sodium delayed-release tablets and evaluate the patient immediately. Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus Avoid use of NSAIDs, including diclofenac sodium delayed-release tablets, in pregnant women at about 30-weeks’ gestation and later.
NSAIDs, including diclofenac sodium delayed-release tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment Use of NSAIDs, including diclofenac sodium delayed-release tablets, at about 20-weeks’ gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.
These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation.
In some postmarketing cases of impaired neonatal renal function, invasive procedures, such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30-weeks’ gestation, limit diclofenac sodium delayed-release tablets use to the lowest effective dose and shortest duration possible.
Consider ultrasound monitoring of amniotic fluid if diclofenac sodium delayed-release tablets treatment extends beyond 48 hours. Discontinue diclofenac sodium delayed-release tablets if oligohydramnios occurs and follow up according to clinical practice (see PRECAUTIONS; Pregnancy). Hematologic Toxicity Anemia has occurred in NSAID-treated patients.
This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect on erythropoiesis. If a patient treated with diclofenac sodium delayed-release tablets, has any signs or symptoms of anemia, monitor hemoglobin or hematocrit. NSAIDs, including diclofenac sodium delayed-release tablets, may increase the risk of bleeding events.
Co-morbid conditions, such as coagulation disorders, concomitant use of warfarin, other anticoagulants, antiplatelet agents (e.g., aspirin), serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding (see PRECAUTIONS; Drug Interactions).
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| ACE inhibitors, ARBs, diuretics ("triple whammy") | Adjust or monitor | Less blood-pressure and diuretic effect; risk of acute kidney injury and hyperkalemia, especially in older, volume-depleted or CKD patients (label). | Avoid the triple combination where possible; if used, check creatinine and potassium within 1 to 2 weeks and keep the patient hydrated. |
| Anticoagulants, antiplatelets (including aspirin), SSRIs, SNRIs | Adjust or monitor | Higher risk of serious bleeding (label). | Avoid if possible; otherwise monitor for bleeding. |
| Other NSAIDs or salicylates | Avoid | More gastrointestinal toxicity without added benefit (label). | Do not combine. |
| Lithium, methotrexate, cyclosporine, digoxin | Adjust or monitor | Higher levels or more nephrotoxicity (NSAID class labeling; not in the stored extract of this label). | Monitor drug levels and kidney function. |
| Strong CYP2C9 inhibitors (e.g., voriconazole) | Adjust or monitor | Higher diclofenac exposure (label). | Consider a lower diclofenac dose (AUC up 78% with voriconazole; label). |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedMetabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
The formation of 4’- hydroxy- diclofenac is primarily mediated by CYP2C9.
Acyl glucuronidation mediated by UGT2B7 and oxidation mediated by CYP2C8 may also play a role in diclofenac metabolism.
CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac.
Drug Interactions Studies Voriconazole: When coadministered with voriconazole (inhibitor of CYP2C9, 2C19, and 3A4 enzyme), the C max and AUC of diclofenac increased by 114% and 78%, respectively (see PRECAUTIONS;
Adverse reactions
Common
- Abdominal pain, dyspepsia, nausea, diarrhea, constipation, flatulence
- Headache, dizziness
- Edema, elevated liver enzymes, rash, tinnitus
Serious
- Cardiovascular thrombotic events (boxed warning)
- Gastrointestinal bleeding, ulceration, perforation (boxed warning)
- Acute kidney injury, papillary necrosis, hyperkalemia
- Heart failure and edema; hypertension
- Hepatotoxicity
- Serious skin reactions, DRESS, anaphylaxis
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: Cardiovascular Thrombotic Events (see WARNINGS) GI Bleeding, Ulceration and Perforation (see WARNINGS) Hepatotoxicity (see WARNINGS) Hypertension (see WARNINGS) Heart Failure and Edema (see WARNINGS) Renal Toxicity and Hyperkalemia (see WARNINGS) Anaphylactic Reactions (see WARNINGS) Serious Skin Reactions (see WARNINGS) Hematologic Toxicity (see WARNINGS) Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In patients taking diclofenac sodium delayed-release tablets, or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1% - 10% of patients are: Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.
Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes, and tinnitus. Additional adverse experiences reported occasionally include: Body as a Whole: fever, infection, sepsis Cardiovascular System: congestive heart failure, hypertension, tachycardia, syncope Digestive System: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice Hemic and Lymphatic System: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia Metabolic and Nutritional: weight changes Nervous System: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia, somnolence, tremors, vertigo Respiratory System: asthma, dyspnea Skin and Appendages: alopecia, photosensitivity, sweating increased Special Senses: blurred vision Urogenital System: cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure Other adverse reactions, which occur rarely are: Body as a Whole: anaphylactic reactions, appetite changes, death Cardiovascular System: arrhythmia, hypotension, myocardial infarction, palpitations, vasculitis Digestive System: colitis, eructation, fulminant hepatitis with and without jaundice, liver failure, liver necrosis, pancreatitis Hemic and Lymphatic System: agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia Metabolic and Nutritional: hyperglycemia Nervous System: convulsions, coma, hallucinations, meningitis Respiratory System: respiratory depression, pneumonia Skin and Appendages: angioedema, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria Special Senses: conjunctivitis, hearing impairment
Monitoring parameters
- Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Liver enzymes within 4 to 8 weeks of starting long-term use (diclofenac hepatotoxicity warning). Kidney
- Serum creatinine and potassium at baseline and during use in CKD, heart failure, cirrhosis, older adults, or with ACE inhibitors, ARBs or diuretics
- Blood pressure; signs of gastrointestinal bleeding; hemoglobin if anemia symptoms
- Liver enzymes periodically during long-term use
Pharmacokinetics
Key PK parameters
| Bioavailability | About 55% (first-pass metabolism) |
|---|---|
| Time to peak | About 2.3 hours |
| Half-life | About 2.3 hours |
| Half-life in kidney failure (ESKD) kidney | Unchanged in kidney impairment (label) |
| Volume of distribution | 1.4 L/kg (apparent) |
| Protein binding | Over 99% (albumin) |
| Metabolism (CYP, transporters) | Hepatic (CYP2C9 and others) to hydroxylated metabolites |
| Active metabolites | Hydroxy metabolites; peak 4'-hydroxy level higher in kidney dysfunction (label) |
| Renal excretion kidney | About 65% of dose in urine as metabolites; under 1% unchanged |
| Dialyzability kidney | Unlikely (label) |
Pharmacokinetic Parameters for Diclofenac PK Parameter Normal Healthy Adults (20 to 48 years) Mean Coefficient of Variation (%) Absolute bioavailability (%) [N = 7] 55 40 T max (hr) [N = 56] 2.3 69 Oral clearance (CL/F; mL/min) [N = 56] 582 23 Renal clearance (% unchanged drug in urine) [N = 7] <1 — Apparent volume of distribution (V/F;
L/kg) [N = 56] 1.4 58 Terminal half-life (hr) [N = 56] 2.3 48 Distribution The apparent volume of distribution (V/F) of diclofenac sodium is 1.4 L/kg.
Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion.
Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.
Little or no free unchanged diclofenac is excreted in the urine.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Mechanism of Action Diclofenac has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of diclofenac sodium delayed-release tablets, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). Diclofenac is a potent inhibitor of prostaglandin synthesis in vitro.
Diclofenac concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Because diclofenac is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.
Pharmacokinetics Absorption Diclofenac is 100% absorbed after oral administration compared to intravenous (IV) administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available (see Table 1). Food has no significant effect on the extent of diclofenac absorption.
However, there is usually a delay in the onset of absorption of 1 to 4.5 hours and a reduction in peak plasma levels of less than 20%. Table 1. Pharmacokinetic Parameters for Diclofenac PK Parameter Normal Healthy Adults (20 to 48 years) Mean Coefficient of Variation (%) Absolute bioavailability (%) [N = 7] 55 40 T max (hr) [N = 56] 2.3 69 Oral clearance (CL/F; mL/min) [N = 56] 582 23 Renal clearance (% unchanged drug in urine) [N = 7] <1 — Apparent volume of distribution (V/F; L/kg) [N = 56] 1.4 58 Terminal half-life (hr) [N = 56] 2.3 48 Distribution The apparent volume of distribution (V/F) of diclofenac sodium is 1.4 L/kg.
Diclofenac is more than 99% bound to human serum proteins, primarily to albumin. Serum protein binding is constant over the concentration range (0.15 to 105 mcg/mL) achieved with recommended doses. Diclofenac diffuses into and out of the synovial fluid. Diffusion into the joint occurs when plasma levels are higher than those in the synovial fluid, after which the process reverses and synovial fluid levels are higher than plasma levels.
It is not known whether diffusion into the joint plays a role in the effectiveness of diclofenac. Elimination Metabolism Five diclofenac metabolites have been identified in human plasma and urine. The metabolites include 4'- hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy-diclofenac. The major diclofenac metabolite, 4'-hydroxy-diclofenac, has very weak pharmacologic activity.
The formation of 4’- hydroxy- diclofenac is primarily mediated by CYP2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acyl glucuronidation mediated by UGT2B7 and oxidation mediated by CYP2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy- and 3’-hydroxy-diclofenac.
In patients with renal dysfunction, peak concentrations of metabolites 4'-hydroxy- and 5-hydroxy-diclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects. Excretion Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites.
Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Because renal elimination is not a significant pathway of elimination for unchanged diclofenac, dosing adjustment in patients with mild to moderate renal dysfunction is not necessary.
The terminal half-life of unchanged diclofenac is approximately 2 hours. Special Populations Pediatric: The pharmacokinetics of diclofenac sodium delayed-release tablets has not been investigated in pediatric patients. Race: Pharmacokinetic differences due to race have not been identified. Hepatic Impairment: Hepatic metabolism accounts for almost 100% of diclofenac sodium delayed-release tablets, elimination, so patients with hepatic disease may require reduced doses of diclofenac sodium delayed-release tablets, compared to patients with normal hepatic function.
Renal Impairment: Diclofenac pharmacokinetics has been investigated in subjects with renal insufficiency. No differences in the pharmacokinetics of diclofenac have been detected in studies of patients with renal impairment. In patients with renal impairment (inulin clearance 60 to 90, 30 to 60, and less than 30 mL/min; N = 6 in each group), area under the curve (AUC) values and elimination rate were comparable to those in healthy subjects.
Drug Interactions Studies Voriconazole: When coadministered with voriconazole (inhibitor of CYP2C9, 2C19, and 3A4 enzyme), the C max and AUC of diclofenac increased by 114% and 78%, respectively (see PRECAUTIONS; Drug Interactions). Aspirin: When NSAIDs were administered with aspirin, the protein binding of NSAIDs were reduced, although the clearance of free NSAID was not altered.
The clinical significance of this interaction is not known. See Table 2 for clinically significant drug interactions of NSAIDs with aspirin (see PRECAUTIONS; Drug Interactions).
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Diclofenac 25 mg/mL, 3 mL Ampule | ₱7.60–₱19.90Reference ₱13.51 | per ampule | DPRI procurement range |
| Diclofenac 50 mg Tablet | ₱0.50–₱2.85Reference ₱0.98 | per tablet | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Diclofenac |
| PNF listing | Oral: 25 mg and 50 mg tablet/capsule (as sodium or potassium salt) |
| PNF listing | Oral: 50 mg enteric coated tablet or MR tablet (as sodium salt) |
| PNF listing | Oral: 100 mg MR tablet/capsule (as sodium or potassium salt) |
| PNF listing | Inj.: 25 mg/mL, 3 mL ampul (IM, IV) (as sodiumsalt) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Diclofenac Sodium · Umedica Laboratories USA Inc. [US FDA-approved label, version 7, October 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e5c6669-390f-4c32-b9b8-13ed3c517462
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Umedica Laboratories USA Inc. (2026). Diclofenac sodium delayed-release tablets [Prescribing information; US FDA-approved label, ANDA219945, set ID 0e5c6669-390f-4c32-b9b8-13ed3c517462, version effective October 23, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e5c6669-390f-4c32-b9b8-13ed3c517462
- Zameer Pharmaceuticals LLC. (2025). Naproxen tablets [Prescribing information; US FDA-approved label, set ID d2e5553a-7c90-407c-9f07-3be65560c23a] (NSAID class labeling, section 7). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d2e5553a-7c90-407c-9f07-3be65560c23a
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .


